C4 Therapeutics (NASDAQ: CCCC) shares 2028 milestones in press release

Rhea-AI Filing Summary

C4 Therapeutics, Inc. filed a Form 8-K to furnish information about a new corporate update. On January 14, 2026, the company issued a press release that outlines its milestones through 2028 and highlights recent achievements, and has attached this press release as Exhibit 99.1.

The disclosure is made under Item 7.01 (Regulation FD Disclosure), which means the information in the press release and Item 7.01 is being furnished rather than filed and is not subject to certain liability provisions of the Exchange Act or automatically incorporated into other securities law filings. The report is signed on behalf of the company by its Chief Financial Officer and Treasurer, Kendra R. Adams.

0001662579false00016625792026-01-142026-01-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________________________________________________

FORM 8-K

_________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 14, 2026

_________________________________________________________________

C4 THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

_________________________________________________________________

Delaware			001-39567			47-5617627
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
490 Arsenal Way,   Suite 120 Watertown,  MA						02472
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 231-0700

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

_________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

CCCC

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 7.01 Regulation FD Disclosure.

On January 14, 2026, C4 Therapeutics, Inc. (the “Company”) issued a press release outlining milestones through 2028 and highlighting recent achievements. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.

Exhibit Number						Description
99.1						Press release issued January 14, 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			C4 Therapeutics, Inc.
Date: January 14, 2026			By:			/s/ Kendra R. Adams
						Kendra R. Adams
						Chief Financial Officer and Treasurer

FAQ

What did C4 Therapeutics (CCCC) report in this Form 8-K?

C4 Therapeutics, Inc. reported that on January 14, 2026 it issued a press release outlining milestones through 2028 and highlighting recent achievements, and furnished this press release as Exhibit 99.1.

What is included in Exhibit 99.1 to C4 Therapeutics Form 8-K?

Exhibit 99.1 is a press release issued by C4 Therapeutics on January 14, 2026 that outlines milestones through 2028 and highlights recent achievements.

Under which item of Form 8-K did C4 Therapeutics furnish the press release?

C4 Therapeutics furnished the press release under Item 7.01, Regulation FD Disclosure.

Is the information in C4 Therapeutics press release considered filed with the SEC?

No. The company states that the information in Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other filings.

Who signed this Form 8-K for C4 Therapeutics?

The Form 8-K was signed on behalf of C4 Therapeutics, Inc. by Kendra R. Adams, the companys Chief Financial Officer and Treasurer.

What other exhibits are referenced in this C4 Therapeutics Form 8-K?

In addition to Exhibit 99.1, the filing references Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.